Shionogi & Co., Ltd. (SGIOF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Shionogi & Co., Ltd. (SGIOF) trades at $16.00 with AI Score 57/100 (Grade B). Shionogi & Co. , Ltd. is a leading pharmaceutical company based in Japan, specializing in the development of innovative drugs and medical devices. Market cap: $13.62B, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for SGIOF: SGIOF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SGIOF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SGIOF: 4/6 perspectives are bullish. Dominant signal: Seth Klarman bullish.
Shionogi & Co., Ltd. (SGIOF) Healthcare & Pipeline Overview
Shionogi & Co., Ltd. stands out in the healthcare sector with its robust pipeline of innovative pharmaceuticals and medical devices, focusing on areas such as infectious diseases, pain management, and mental health, thereby addressing significant unmet medical needs.
What Is the Investment Thesis for SGIOF?
Shionogi & Co., Ltd. is positioned for sustained growth driven by its diverse and innovative pipeline, which includes treatments for critical areas such as infectious diseases and mental health. The company boasts a robust profit margin of 41.9% and a gross margin of 84.3%, reflecting its operational efficiency and strong pricing power. Upcoming catalysts include the potential approval and market launch of several key products in development, such as S-120083 for inflammatory pain and S-723595 for NASH, which could significantly enhance revenue streams. Furthermore, Shionogi's strategic collaborations with research institutions may accelerate the development of novel therapies, providing a competitive edge. However, investors should remain cautious of ongoing regulatory challenges and market competition that could impact growth trajectories.
Based on FMP financials and quantitative analysis
SGIOF Key Highlights
- Market Cap of $20.11B, reflecting strong market confidence in Shionogi's innovative pipeline.
- P/E ratio of 15.17, indicating a favorable valuation compared to industry peers.
- Profit Margin of 41.9%, showcasing operational efficiency and effective cost management.
- Gross Margin of 84.3%, significantly higher than the industry average, highlighting strong pricing power.
- Dividend Yield of 1.78%, providing a return to shareholders amidst growth investments.
Who Are SGIOF's Competitors?
SGIOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBHF Alibaba Health Information Technology Limited | $0.45 | +0.00% | $7.26B | 45 |
| BIOVF Swedish Orphan Biovitrum AB (publ) | $48.00 | +0.00% | $16.60B | 56 |
| BMXMF bioMérieux S.A. | $77.32 | -8.03% | $9.12B | 52 |
| CHJTF CSPC Pharmaceutical Group Limited | $1.05 | +0.00% | $11.98B | 50 |
| FMCQF Fresenius Medical Care AG & Co. KGaA | $45.17 | +0.00% | $12.13B | 46 |
| ALVO Alvotech | $4.44 | +5.21% | $1.39B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SGIOF's Key Strengths?
- Robust pipeline of innovative drugs targeting high unmet medical needs.
- Strong financial performance with high profit and gross margins.
- Established collaborations with leading research institutions.
- Long-standing reputation and experience in the pharmaceutical industry.
What Are SGIOF's Weaknesses?
- Dependence on a limited number of key products for revenue.
- Challenges in navigating complex regulatory environments.
- Potential delays in drug development timelines impacting market entry.
- Limited geographic diversification outside Japan.
What Could Drive SGIOF Stock Higher?
- Potential approval and market launch of S-120083 for inflammatory pain.
- Advancements in COVID-19 treatment pipeline with S-600918 and S-217622.
- Strategic collaborations with research institutions enhancing drug development capabilities.
- Expansion into new therapeutic areas such as obesity and mental health.
- Continuous investment in R&D to innovate and meet market needs.
What Are the Key Risks for SGIOF?
- Regulatory challenges impacting drug approval timelines.
- Competitive pressures from other pharmaceutical companies in key markets.
- Market volatility affecting pricing strategies and revenue stability.
- Risks associated with clinical trial outcomes and product efficacy.
What Are the Growth Opportunities for SGIOF?
- Growth opportunity 1: Shionogi's development of S-120083 for inflammatory pain presents a significant market opportunity, as the global pain management market is expected to reach $100 billion by 2025. With a growing patient population seeking effective pain relief, successful commercialization of this drug could lead to substantial revenue growth.
- Growth opportunity 2: The expansion of Shionogi's portfolio to include treatments for NASH with S-723595 taps into a burgeoning market projected to exceed $35 billion by 2026. As the prevalence of non-alcoholic fatty liver disease rises, Shionogi's innovative solutions could capture significant market share.
- Growth opportunity 3: Shionogi's ongoing research into COVID-19 treatments, including S-600918 and S-217622, aligns with the urgent need for effective therapies in a post-pandemic world. The global market for COVID-19 therapeutics is projected to remain robust, offering Shionogi a chance to capitalize on its research advancements.
- Growth opportunity 4: The company's commitment to developing therapies for mental health, particularly Zuranolone for depression, addresses a critical area of need. The global antidepressant market is expected to reach $15 billion by 2025, positioning Shionogi to benefit from increasing awareness and treatment adoption.
- Growth opportunity 5: Shionogi's collaboration with academic institutions for antimalarial drug development opens avenues for public-private partnerships, enhancing its research capabilities and potentially leading to breakthrough therapies in infectious diseases, a market poised for growth.
What Opportunities Does SGIOF Have?
- Expansion into emerging markets with growing healthcare needs.
- Development of novel therapies for chronic conditions and infectious diseases.
- Strategic partnerships to enhance research capabilities and funding.
- Increased focus on mental health treatments in response to rising demand.
What Threats Does SGIOF Face?
- Intense competition from other pharmaceutical companies.
- Potential regulatory changes impacting drug approval processes.
- Market volatility affecting pricing and reimbursement strategies.
- Risks associated with clinical trial failures and product recalls.
What Are SGIOF's Competitive Advantages?
- Strong research and development capabilities leading to innovative product offerings.
- Established brand reputation and trust in the pharmaceutical industry.
- Collaborative partnerships with leading academic institutions enhancing research potential.
- Diverse product portfolio addressing multiple therapeutic areas reducing dependency on single products.
- High barriers to entry in the pharmaceutical sector due to regulatory requirements.
What Does SGIOF Do?
Founded in 1878, Shionogi & Co., Ltd. has evolved from a small pharmaceutical firm into a significant player in the global healthcare landscape. Originally known as Shionogi Shoten Co., Ltd., the company rebranded in 1943 to reflect its broader ambitions. Headquartered in Osaka, Japan, Shionogi engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its product portfolio includes notable drugs such as Fetroja for multidrug-resistant bacterial infections, Xofluza for influenza, and Tivicay for HIV treatment. The company is also advancing a range of innovative therapies for conditions including opioid-induced constipation, neuropathic pain, insomnia, and depression. Shionogi's commitment to research is underscored by its collaboration agreements with prestigious institutions like Nagasaki University and the National Institute of Infectious Diseases to develop antimalarial drugs. With approximately 4,955 employees, Shionogi maintains a strong presence in Japan and is expanding its reach globally, leveraging its expertise in drug development to meet the evolving needs of patients worldwide.
What Products and Services Does SGIOF Offer?
- Research, develop, manufacture, and distribute pharmaceuticals and medical devices.
- Offer a diverse range of products targeting infectious diseases, pain management, and mental health.
- Develop innovative therapies for chronic conditions such as obesity and neuropathic pain.
- Engage in collaborations with academic institutions for drug development.
- Provide diagnostic reagents and medical devices to healthcare providers.
- Conduct clinical trials to advance new therapeutic options.
How Does SGIOF Make Money?
- Generate revenue through the sale of prescription pharmaceuticals and medical devices.
- Leverage partnerships and collaborations for research and development funding.
- Invest in innovative drug development to address unmet medical needs.
- Utilize a robust supply chain for efficient distribution of products.
- Focus on high-margin specialty drugs to enhance profitability.
What Industry Does SGIOF Operate In?
The pharmaceutical industry, particularly the specialty and generic drug sector, is experiencing robust growth, driven by increasing healthcare demands and advancements in biotechnology. The global market for pharmaceuticals is projected to reach $1.5 trillion by 2023, with a notable shift towards personalized medicine and innovative therapies. Shionogi & Co., Ltd. is well-positioned within this landscape, leveraging its research capabilities and product pipeline to compete effectively against peers such as ALBHF, BIOVF, and CHJTF. The company's focus on high-demand therapeutic areas aligns with market trends, positioning it for future success.
Who Are SGIOF's Key Customers?
- Healthcare providers including hospitals and clinics.
- Pharmacies and distributors of pharmaceutical products.
- Patients requiring specialized medical treatments.
- Research institutions and universities for collaborative projects.
- Government and private healthcare organizations for public health initiatives.
SGIOF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $139.87B | $47.23B | $55.48 |
| Q4 2025 | $147.85B | $74.75B | $87.83 |
| Q3 2025 | $114.80B | $44.82B | $52.65 |
| Q2 2025 | $100.26B | $39.55B | $46.47 |
Based on FMP financials and quantitative analysis
SGIOF Latest News
-
Stocks That Hit 52-Week Highs On Friday
· Jan 17, 2020
SGIOF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SGIOF.
Price Targets
Wall Street price target analysis for SGIOF.
SGIOF MoonshotScore
What does this score mean?
The MoonshotScore rates SGIOF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Isao Teshirogi
CEO
Isao Teshirogi has been at the helm of Shionogi & Co., Ltd. since 2011, bringing over three decades of experience in the pharmaceutical industry. He holds a degree in pharmacy from Kyoto University and has held various leadership roles within Shionogi, focusing on research and development, marketing, and corporate strategy. His extensive background in drug development and market expansion has been instrumental in driving the company's growth.
Track Record: Under Teshirogi's leadership, Shionogi has successfully launched several key products and expanded its research pipeline significantly. His strategic vision has led to increased collaborations with academic institutions and a strengthened focus on innovative therapies, positioning the company for future growth.
SGIOF OTC Market Information
The OTC Other tier represents stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. Companies in this tier may have less stringent reporting and regulatory requirements, which can lead to lower liquidity and higher volatility compared to listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures may hinder transparency for investors.
- Lower trading volumes can lead to price volatility and execution challenges.
- Potential regulatory scrutiny specific to OTC stocks may impact operations.
- Increased risk of fraud or misrepresentation in the OTC market.
- Verify the company's financial health through available reports.
- Assess the management team's track record and industry experience.
- Research the competitive landscape and market positioning.
- Evaluate the product pipeline and upcoming catalysts.
- Monitor regulatory developments that may impact the company.
- Established history and reputation in the pharmaceutical industry.
- Partnerships with reputable academic and research institutions.
- Compliance with regulatory standards in drug development.
- Availability of clinical trial data and research publications.
Common Questions About SGIOF (Healthcare)
What does Shionogi & Co., Ltd. do?
Shionogi & Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacture, and distribution of innovative drugs and medical devices. The company focuses on addressing unmet medical needs across various therapeutic areas, including infectious diseases, pain management, and mental health, with a diverse portfolio of products.
What do analysts say about SGIOF stock?
Analysts generally view Shionogi & Co., Ltd. as a solid player in the pharmaceutical sector, noting its strong financial metrics such as a 41.9% profit margin and 84.3% gross margin. The company's innovative pipeline and strategic collaborations are highlighted as key growth considerations, although potential regulatory challenges are acknowledged.
What are the main risks for SGIOF?
Shionogi & Co., Ltd. faces several risks, including potential regulatory hurdles that could delay drug approvals and market entry. Ongoing competitive pressures from other pharmaceutical companies may impact market share, while the volatility associated with the OTC market could affect stock performance. Additionally, the company must navigate the complexities of clinical trial outcomes that could influence product viability.
What are the key factors to evaluate for SGIOF?
Shionogi & Co., Ltd. (SGIOF) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does SGIOF data refresh on this page?
SGIOF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SGIOF's recent stock price performance?
Shionogi & Co., Ltd. (SGIOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Robust pipeline of innovative drugs targeting high unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SGIOF overvalued or undervalued right now?
Valuing Shionogi & Co., Ltd. (SGIOF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SGIOF?
Before investing in Shionogi & Co., Ltd. (SGIOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available information; potential discrepancies may exist due to the OTC classification.